Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains; Laurent Godinas; F J Sherida H Woei-A-Jin; Wouter Rosseels; Yannick Van Herck; Natalie Lorent; Daan Dierickx; Veerle Compernolle; Geert Meyfroidt; Lore Vanderbeke; Valentijn Vergote; Katrien Lagrou; Peter Verhamme; Joost Wauters; Pieter Vermeersch; Timothy Devos; Piet Maes; Steven Vanderschueren

doi:10.1111/bjh.17266

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Br J Haematol. 2021 Mar;192(6):1100-1105. doi: 10.1111/bjh.17266. Epub 2020 Dec 13.

Authors

Albrecht Betrains^{1

2}, Laurent Godinas³, F J Sherida H Woei-A-Jin^{4

5}, Wouter Rosseels¹, Yannick Van Herck⁴, Natalie Lorent³, Daan Dierickx^{6

7}, Veerle Compernolle^{8

9}, Geert Meyfroidt^{10

11}, Lore Vanderbeke^{1

12}, Valentijn Vergote¹³, Katrien Lagrou¹⁴, Peter Verhamme^{15

16}, Joost Wauters^{1

2}, Pieter Vermeersch¹⁴, Timothy Devos^{6

17}, Piet Maes¹³, Steven Vanderschueren^{1

2}

Affiliations

¹ Department of General Internal Medicine, UZ Leuven, Leuven, Belgium.
² Department of Microbiology, Immunology, and Transplantation, Laboratory of clinical infectious and inflammatory diseases, KU Leuven, Leuven, Belgium.
³ Department of Respiratory Diseases, UZ Leuven, Leuven, Belgium.
⁴ Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.
⁵ Department of General Medical Oncology, University Hospitals, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.
⁶ Department of Hematology, University Hospitals, UZ Leuven, Leuven, Belgium.
⁷ Department of Oncology, Laboratory of Experimental Hematology, KU Leuven, Leuven, Belgium.
⁸ Blood Services, Belgian Red Cross-Flanders, Mechelen, Belgium.
⁹ Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
¹⁰ Department of Intensive Care Medicine, UZ Leuven, Leuven, Belgium.
¹¹ Department and Laboratory of Intensive Care Medicine, KU Leuven, Leuven, Belgium.
¹² Department of Microbiology, Immunology, and Transplantation, Laboratory of Clinical Bacteriology and Mycology, KU Leuven, Leuven, Belgium.
¹³ Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium.
¹⁴ Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Disease Pathogens, University Hospitals Leuven, Leuven, Belgium.
¹⁵ Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium.
¹⁶ Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
¹⁷ Department of Microbiology, Immunology, and Transplantation, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.

PMID: 33314018
DOI: 10.1111/bjh.17266

No abstract available

Keywords: B-cell depletion; anti-CD20; neutralising antibodies; protracted COVID-19; rituximab.

Publication types

Letter

MeSH terms

Antibodies, Neutralizing / therapeutic use*
COVID-19 / immunology
COVID-19 / therapy*
COVID-19 Serotherapy
Female
Humans
Immunity, Humoral
Immunization, Passive
Lymphoma / immunology*
Lymphoma / virology*
Male

Substances

Antibodies, Neutralizing